Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Breast CancerMetastatic Castration-resistant Prostate Carcinoma
Interventions
OTHER

Lean body mass

Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose

OTHER

Total body weight

Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose

OTHER

bloodsampling

Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model

Trial Locations (2)

Unknown

Deventer Hospital, Deventer

Radboud University Nijmegen Medical Centre, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT01621425 - Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity | Biotech Hunter | Biotech Hunter